TY - JOUR
T1 - One-year outcomes in 1,010 unselected patients treated with the PROMUS Element everolimus-eluting stent
T2 - the multicentre PROMUS Element European Post-Approval Surveillance Study
AU - Thomas, Martyn R.
AU - Birkemeyer, Ralf
AU - Schwimmbeck, Peter
AU - Legrand, Victor
AU - Moreno, Raul
AU - Briguori, Carlo
AU - Werner, Nikos
AU - Bramucci, Ezio
AU - Ungi, Imre
AU - Richardt, Gert
AU - Underwood, Paul L.
AU - Dawkins, Keith D.
PY - 2015/3/1
Y1 - 2015/3/1
N2 - AIMS: The PROMUS™ Element™ European Post-Approval Surveillance Study (PE-Prove) is a prospective, open-label, multicentre observational study designed to assess outcomes following PROMUS Element everolimus-eluting stent implantation in an unselected patient population.METHODS AND RESULTS: A total of 1,010 patients were enrolled at 40 clinical sites in Europe, including 24.9% with medically treated diabetes, 50.0% with Type B2/C lesions, 6.1% with chronic total occlusion, 17.8% with acute myocardial infarction (MI ≤24 hours pre-procedure), and 20.1% with unstable angina. The target lesion was the culprit for ST-segment elevation MI in 7.3% of patients. The one-year, per patient target vessel failure rate was 6.2% (60/975), 3.4% (33) being related to the PROMUS Element stent. Rates of cardiac death, MI, and Academic Research Consortium (ARC) definite/probable stent thrombosis were 1.7%, 3.5%, and 0.6%, respectively. The target vessel revascularisation rate was 3.2% (31/975), 2.1% (20) being related to the PROMUS Element stent.CONCLUSIONS: In a large and relatively complex group of "real-world" patients, coronary artery revascularisation with the PROMUS Element everolimus-eluting stent provides favourable results with low event rates consistent with those reported for other contemporary drug-eluting stents.
AB - AIMS: The PROMUS™ Element™ European Post-Approval Surveillance Study (PE-Prove) is a prospective, open-label, multicentre observational study designed to assess outcomes following PROMUS Element everolimus-eluting stent implantation in an unselected patient population.METHODS AND RESULTS: A total of 1,010 patients were enrolled at 40 clinical sites in Europe, including 24.9% with medically treated diabetes, 50.0% with Type B2/C lesions, 6.1% with chronic total occlusion, 17.8% with acute myocardial infarction (MI ≤24 hours pre-procedure), and 20.1% with unstable angina. The target lesion was the culprit for ST-segment elevation MI in 7.3% of patients. The one-year, per patient target vessel failure rate was 6.2% (60/975), 3.4% (33) being related to the PROMUS Element stent. Rates of cardiac death, MI, and Academic Research Consortium (ARC) definite/probable stent thrombosis were 1.7%, 3.5%, and 0.6%, respectively. The target vessel revascularisation rate was 3.2% (31/975), 2.1% (20) being related to the PROMUS Element stent.CONCLUSIONS: In a large and relatively complex group of "real-world" patients, coronary artery revascularisation with the PROMUS Element everolimus-eluting stent provides favourable results with low event rates consistent with those reported for other contemporary drug-eluting stents.
UR - http://www.scopus.com/inward/record.url?scp=84952308966&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84952308966&partnerID=8YFLogxK
U2 - 10.4244/EIJY15M01_07
DO - 10.4244/EIJY15M01_07
M3 - Article
C2 - 25631367
SN - 1774-024X
VL - 10
SP - 1267
EP - 1271
JO - EuroIntervention
JF - EuroIntervention
IS - 11
ER -